Key Data and Outcomes from the GRIFFIN Trial
A summary of updates from the GRIFFIN trial evaluating D-RVd in clinically relevant NDMM patient subgroups.
Video Player is loading.
EP: 1.An Introduction to NDMM: Treatment Options and Patient Risk Stratification
EP: 2.Clinical Insights from the Results of the MASTER Trial
Now Viewing
EP: 3.Key Data and Outcomes from the GRIFFIN Trial
EP: 4.A Practical Approach to Treatment Selection for Patients with NDMM
EP: 5.Optimizing Consolidation and Maintenance Therapy in the NDMM Treatment Landscape
EP: 6.The Future of the NDMM: Comparing Emergent Regimens and Understanding Unmet Needs
EP: 7.Recap: Available Treatment Options in Transplant-Eligible Multiple Myeloma
Recent Videos
Future of HER2-Directed Tumor-Agnostic Therapies
Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
HER2 Key Differences and Current Approaches to Biomarker Testing
Introduction to HER2-Directed Tumor-Agnostic Approaches
Clinical Pearls Surrounding the Use of Bispecifics in R/R MM
R/R MM Treatment Landscape: Role of Bispecifics
Future Perspectives in R/R MM
Bispecifics in R/R MM: AE Management and Sequencing
